News and Trends 31 Mar 2023 Destiny Pharma gel reduces nasal staph in surgery patients Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections. The data was published in the journal Infection Control & Hospital Epidemiology. The paper was […] March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by MC Services 10 Mar 2023 Meet some of the biotechs attending Bio-Europe Spring 2023 As Bio-Europe Spring 2023 is set to take place from March 20 to March 22 in Basel, Switzerland, a budding biotech hub, the event will provide opportunities to engage with representatives of hundreds of companies from around the world. At the convention, exhibitors will be able to showcase their innovations and meet with prospective sponsors, […] March 10, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 15 Nov 2022 Destiny Pharma’s XF-73 dermal infection project advances to safety study The second of two planned preclinical safety studies has started for Destiny Pharma’s XF-73 dermal formulation. The company announced the start of an investigational new drug (IND) today (November 15) and is developing the formulation for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs). This second study […] November 15, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Good news for Destiny Pharma’s nasal gel to combat life-threatening infections Clinical stage biotech company, Destiny Pharma, announced today (July 19) a positive update from the U.S. Food and Drug Administration (FDA) on its XF-73 nasal gel phase 3 development plans. The FDA has clarified the phase 3 and U.S. registration pathway for the gel for the prevention of post-surgical staphylococcal infections, and this feedback enables […] July 19, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jul 2022 Treatments set to improve for lethal lung disease and ulcers following drug synergy data revelation New data has been published today (July 7) evidencing findings that could lead to better treatment for people with lethal lung infections and infected diabetic foot ulcers caused by antimicrobial resistant (AMR) bacteria. Clinical stage biotechnology company, Destiny Pharma plc., focused on the development of novel products to prevent life-threatening infections, revealed the publication of […] July 7, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email